Document and Entity Information Document Information [Table] Document Information [Line Items] Document and Entity Information Document Type Entity Registrant Name Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Central Index Key Amendment Flag Condensed Consolidated Balance Sheets Statement [Table] Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Domain] Nonrelated Party [Member] Non related party Related Party [Member] Related party Statement [Line Items] Statement Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets Cash Cash Financing Receivable, after Allowance for Credit Loss, Current Loan receivable Deferred Costs, Current Deferred transaction costs Prepaid Expense and Other Assets, Current Prepaid and other current assets Assets, Current Total current assets Assets, Noncurrent [Abstract] Non-current assets Other Receivable, after Allowance for Credit Loss, Noncurrent Due from related party, non-current Property, Plant and Equipment, Net Property and equipment, net Assets, Noncurrent Total non-current assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' DEFICIT LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities, Current [Abstract] Current liabilities Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Amount of accrued interest as of the balance sheet date. Accrued Interest, Current Accrued interest, related parties Other Liabilities, Current Due to related parties Short-Term Debt Short-term debt, related parties Amount borrowed Amount of deferred underwriting fees payable in cash and are classified as current as of the balance sheet date. Deferred Underwriting Fees Payable In Cash, Current Deferred underwriting fee payable Fair value of common stock payable. Common Stock Payable Settlement payable Liabilities, Current Total current liabilities Warrants and Rights Outstanding Warrant liability Liabilities Total liabilities Commitments and Contingencies Commitments and Contingencies (Note 7) Equity, Attributable to Parent [Abstract] Stockholders' deficit Preferred Stock, Value, Issued Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding Common Stock, Value, Issued Common stock, $0.0001 par value; 500,000,000 shares authorized; 44,877,633 and 27,064,633 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively Common stock, $0.0001 par value; 500,000,000 shares authorized; 27,064,633 and 17,500,000 shares issued and outstanding as of December 31, 2025 and 2024, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Equity, Attributable to Parent Ending balance Beginning balance Total stockholders' deficit Liabilities and Equity Total liabilities and stockholders' deficit Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized (in shares) Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized (in shares) Common stock, shares authorized Common Stock, Shares, Issued Ending balance (in shares) Beginning balance (in shares) Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Condensed Consolidated Statements of Operations General and Administrative Expense General and administrative Research and Development Expense Research and development Research and development expense related to the CD47 License Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Loss from operations Loss from operations Nonoperating Income (Expense) [Abstract] Other income (expense): Interest Expense, Nonoperating Interest expense, related parties Investment Income, Interest Interest income Amount of forgiveness of unrelated vendor payable. Forgiveness Of Unrelated Vendor Payable Forgiveness of unrelated vendor payables Forgiveness of unrelated vendor payables Amount of increase (decrease) from change in fair value of deferred underwriting fees that would be settled in common stock of the combined entity. Equity Settlement, Deferred Underwriting Fees, Effect Of Change In Fair Value Change in fair value of deferred underwriting fee - paid in common stock Change in fair value of deferred underwriting fee - paid in common stock Change in fair value of deferred underwriting fee - paid in common stock Change in fair value of deferred underwriting fee - paid in common stock Fair Value Adjustment of Warrants Change in the fair value of warrant liabilities Change in the fair value of warrant liability Change in the fair value of warrant liabilities Amount of expense related to fair value of common stock to be issued for contingent liability. Fair Value Of Common Stock Issuance For Contingent Liability Fair value of common stock to be issued for contingent liability Fair value of common stock to be issued for contingent liability Nonoperating Income (Expense) Total other expense, net Net Income (Loss) Attributable to Parent Net loss Net loss Net loss Weighted Average Number of Shares Outstanding, Basic Weighted average shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted average shares outstanding - diluted (in shares) Earnings Per Share, Basic Basic net loss per share (in dollars per share) Earnings Per Share, Diluted Diluted net loss per share (in dollars per share) Condensed Consolidated Statements of Changes in Stockholders' Deficit Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Common stock Additional Paid-in Capital [Member] Additional Paid in Capital Additional Paid-in Capital Retained Earnings [Member] Accumulated Deficit Number of shares issued during the period for surrender and cancellation of warrants. Stock Issued during The Period, Shares, Surrender And Cancellation Of Warrants Issuance of common stock in connection with the Clear Street settlement (in shares) Value of shares issued during the period for surrender and cancellation of warrants. Stock Issued during The Period, Values, Surrender And Cancellation Of Warrants Issuance of common stock in connection with the Clear Street settlement Value of stock issued pursuant to business combination during the period. Stock Issued During Period Value Business Combination Business combination with IRIS, net of transaction costs Number of shares of stock issued during the period pursuant to business combination. Stock Issued During Period, Shares, Business Combination Business combination with IRIS, net of transaction costs (in shares) Amount of decrease to additional paid in capital (APIC) resulting from Settlement of loans. Adjustments to Additional Paid in Capital, Settlement of Loans Settlement of loans to Iris Acquisition Corp upon closing of the business combination Stock Issued During Period, Value, Acquisitions Issuance of common stock to Iris Acquisition Holdings, LLC Stock Issued During Period, Shares, Acquisitions Issuance of common stock to Iris Acquisition Holdings, LLC (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock for the PIPE investment Issuance of common stock in connection with the Offering, net of offering costs of $559,962 Stock Issued During Period, Shares, New Issues Number of shares issued (in shares) Issuance of common stock in connection with the Offering, net of offering costs of $559,962 (in shares) Number of shares issued value of common stock to underwriter Stock issued Period Value of Common Stock to Underwriter Issuance of common stock to underwriter Number of shares issued of common stock to underwriter Stock issued Period of Common Stock to Underwriter Issuance of common stock to underwriter (In shares) Number of shares issued value for surrender and cancellation of warrants. Stock issued Period Value For Surrender And Cancellation Of Warrants Issuance of common stock in connection with the surrender of warrants Amount of offering costs involved in the issuance of common stock. Offering Costs Offering costs Allocated Issuance Costs Condensed Consolidated Statements of Cash Flows Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Cash Flows from Operating Activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Adjustments to reconcile net loss to net cash used in operating activities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Amount of receivable deemed as uncollectible and written off. Other Receivable, Write Off Forgiveness of related party receivables Uncollectible due from related party Depreciation Depreciation Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities Increase (Decrease) in Due from Related Parties, Current Due from related party, current Increase (Decrease) in Prepaid Expense and Other Assets Prepaid and other current assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Amount of increase (decrease) in accrued interest to related party classified as current. Increase (Decrease) In Accrued Interest to Related Party, Current Accrued interest, related parties Amount of increase (decrease) in accrued maintenance fee classified as current. Increase (Decrease) In Accrued Maintenance Fees, Current Accrued maintenance fee Amount of increase (decrease) in due to research and development partner classified as current. Increase (Decrease) In Due to Research And Development Partner, Current Due to research and development partner Increase (Decrease) in Due to Related Parties, Current Due to related parties Due to related party Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Net cash used in operating activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Cash Flows from Investing Activities: Cash Flows from Investing Activities Payments to Acquire Loans Receivable Loans to Iris Acquisition Corp Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Net cash used in investing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Cash Flows from Financing Activities: Proceeds from Issuance of Private Placement Gross proceeds from issuance of common stock for PIPE investment Proceeds from issuance of common stock, net Payments of Merger Related Costs, Financing Activities Payment of transaction costs Proceeds from Short-Term Debt Proceeds from issuance of short-term debt, related party Proceeds from bonds Repayments of Short-Term Debt Repayment of short-term debt, related party Repayment of debt Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Net cash provided by financing activities Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Net change in cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Cash, end of the period Cash, beginning of the period Noncash Investing and Financing Items [Abstract] Non-cash investing and financing activities: Liabilities Assumed Liabilities assumed in connection with the Business Combination Value of shares issued or issuable to underwriters upon consummation of business combination in a non-cash transaction. Stock Issued Or issuable To Underwriters Upon Consummation Of Business Combination Fair value of shares to be issued to underwriter on date of the Business Combination The amount of transaction costs incurred upon closing of merger during the period in a non-cash or part non-cash transaction. Merger Transaction Costs Incurred In Noncash Or Partial Noncash Transaction Transaction costs incurred upon closing of the Business Combination Amount of loans settled upon closing of merger in a non-cash transaction. Loans Settled Settlement of loans to Iris Acquisition Corp upon closing of the Business Combination Stock Issued Issuance of common stock to Iris Acquisition Holdings, LLC The amount of borrowed funds for PIPE transactions that are converted in a non-cash or part non-cash transactions. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Noncash Conversion Of Amount Borrowed For PIPE Funds Non-cash conversion of short term debt, related parties for PIPE Funds Amount of non-cash impact to additional paid in capital upon forgiveness of accrued interest on the converted debt instrument in a non-cash transaction. Debt Conversion, Noncash Impact To Additional paid In Capital For Forgiveness Of Accrued Interest Non-cash impact to APIC for the forgiveness of accrued interest on converted related party debt The fair value of stock issuable to underwriters upon closing of merger in a non-cash financing activities. Shares Issuable Upon Closing Of Merger To Underwriters Issuance of common stock to underwriter The fair value of stock issued in connection with settlement in noncash financing activities. Common Stock Issued In Connection With Settlement Issuance of common stock in connection with the Clear Street settlement The amount of common stock issuance costs that were incurred during a noncash or partial noncash transaction. Costs Incurred In Connection With Issuance Of Common Stock Costs incurred in connection with the issuance of common stock Amount of deferred transaction costs in accounts payable. Deferred Transaction Costs In Accounts Payable Deferred transaction costs in accounts payable Description of Organization and Business Operations Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Description of Organization and Business Operations Significant Accounting Policies Significant Accounting Policies [Text Block] Significant Accounting Policies n/a License Agreements The entire disclosure for License Agreements. License Agreements [Text Block] License Agreements Related Party Transactions Related Party Transactions Disclosure [Text Block] Related Party Transactions Debt Debt Disclosure [Text Block] Debt Stockholder's Equity Equity [Text Block] Stockholder's Equity Commitments and Contingencies. Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Disclosure of accounting policies on emerging growth company status. Emerging Growth Company Policy [Policy Text Block] Emerging Growth Company Status Use of Estimates, Policy [Policy Text Block] Use of Estimates Segment Reporting, Policy [Policy Text Block] Segments Cash and Cash Equivalents, Policy [Policy Text Block] Cash Financing Receivable [Policy Text Block] Loan Receivable Deferred Charges, Policy [Policy Text Block] Deferred Transaction Costs Fair Value Measurement, Policy [Policy Text Block] Fair Value of Financial Instruments Disclosure of accounting policy for warrants. Warrants, Policy [Policy Text Block] Warrants Disclosure of policy for net income (loss) per common stock. Net income (loss) per Common Stock Policy [Policy Text Block] Net Loss per Share of Common Stock Net loss per Common Stock Research and Development Expense, Policy [Policy Text Block] Research and Development Expenses Lessee, Leases [Policy Text Block] Leases Income Tax, Policy [Policy Text Block] Income Taxes New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements - Not Yet Adopted Recently Adopted Accounting Pronouncements Schedule of Short-Term Debt [Table Text Block] Schedule of debt outstanding Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Schedule of assumptions used for estimating fair value of warrants Tabular disclosure of offering proceeds and related issuance costs. Schedule of Offering Proceeds and Related Issuance Costs [Table Text Block] Schedule of offering proceeds and related issuance costs Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of fair value, assets and liabilities measured on recurring basis. Tabular disclosure of the fair value measurement of assets and liability using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset and liability. Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of changes in fair value of Level 3 financial assets and liabilities Business Combination [Table] Business Combination [Axis] Business Combination [Domain] Represents information pertaining to business combination with Liminatus and Iris. Liminatus And Iris [Member] Liminatus and Iris Legal Entity [Axis] All Entities [Member] Represents information pertaining to Iris Acquisition Corp. Iris Acquisition Corp [Member] Iris Represents the information pertaining to Iris Acquisition Holdings, LLC. Iris Acquisition Holdings, LLC [Member] Iris Acquisition Holdings, LLC Class of Stock [Axis] Class of Stock [Domain] Common Class A [Member] Class A shares Common Stock Debt Instrument [Axis] Debt Instrument, Name [Domain] Represent the information pertaining to consortium loan of related parties. Consortium Loan of Related Parties [Member] Consortium Loan of related parties Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents information pertaining to non-redeemable warrant. Non Redeemable Warrant [Member] Non-redeemable warrant Represents information pertaining to redeemable warrant. Redeemable Warrant [Member] Redeemable warrant Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Private Placement [Member] Private placement Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Represents information pertaining to Feelux bonds. Feelux Co. Ltd [Member] Feelux Co. Ltd Represents the information pertaining to Feelux and Car-Tcellkor. Feelux and Car-Tcellkor [Member] Feelux and Car-Tcellkor Business Combination [Line Items] Description of Organization and Business Operations Represents the number of common shares redeemed for cash. Common Stock, Cash Redemption, Shares Shares redeemed (in shares) Shares redeemed The price per share at which the common stock of the entity is redeemed or may be called at. Common Stock, Cash Redemption Price Per Share Cash redemption price per share (in dollars per share) Cash redemption price per share Aggregate cash redemption of value of common stock of the entity. Common Stock, Cash Redemption Amount Aggregate cash redemption amount Represents the number of common shares held in each Iris unit. Number Of Shares Held In Each Unit Number of shares held in each unit (in shares) Number of shares held in each unit Represents the number of warrants held in each Iris unit. Number Of Warrants Held In Each Unit Number of warrants held in each unit (in shares) Number of warrants held in each unit Number of common shares issuable upon conversion for each share of common stock in business combination. Common Stock, Conversion Ratio, Business Combination Number of common shares converted Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of shares called by each warrant (in shares) Number of shares called by each warrant Class of Warrant or Right, Exercise Price of Warrants or Rights Price per share (in dollars per share) Exercise price of warrants The maximum number of cumulative shares of all kinds permitted to be issued by an entity's charter and bylaws. Shares Authorized Shares authorized (in shares) Shares authorized Conversion of Stock, Shares Converted Conversion of stock (in shares) Conversion of stock Conversion of Stock, Shares Issued Number of shares converted into (in shares) Number of shares converted into Proceeds from Issuance of Common Stock Total consideration Number of common stock issuable upon conversion of each share of stock or unit to be converted. Conversion Of Stock Or Unit, Conversion Ratio Share conversion ratio The cash inflow associated with the amount received from entity's raising of capital via private placement investor rather than public placement. Proceeds from Issuance of Private Placement Investor Proceeds from issuance of private placement investor The cash inflow associated with the amount received from private placement investor funded indirectly. Proceeds from Issuance of Private Placement Investor Funded Proceeds from issuance of private placement investor funded Debt Conversion, Original Debt, Amount Conversion of related party short-term debt into common stock Amount of principal and accrued interest converted into shares. Principal and Accrued Interest on Private Placement Principal and accrued interest Amount of borrowed from the related parties were used to fund an unsecured promissory note. Related Parties Debt to Unsecured Promissory Note Related parties debt Amount of unsecured promissory note was settled and related party debts were ultimately converted into shares of the Company in a noncash transaction. Unsecured Promissory Note Settled and Converted Unsecured promissory note settled and converted Amount of conversion of principal and accrued interest amount. Conversion of Principal and Accrued Interest Amount Conversion of principal and accrued interest amount Shares of conversion of principal and accrued interest. Conversion of Principal and Accrued Interest Shares Conversion of principal and accrued interest shares (in shares) Conversion of principal and accrued interest shares Business Combination, Recognized Liability Assumed, Liability Recognized liability assumed Payments to Acquire Businesses, Gross Payments to acquire businesses Amount of accrued interest on related party debts that were converted into common stock. Conversion of Accrued Interest on Related party Debts Accrued interest Amount of deferred underwriting fees liabilities of acquiree to be settled by way of issuance of common stock of the entity upon consummation of business combination. Deferred Underwriting Fees Payable, To Be Settled In Shares Upon Consummation Of Business Combination Deferred underwriting fees payable Deferred underwriting fees liabilities Number of shares issuable for settlement of deferred underwriting fees in connection with the underwriting services provided by the underwriters in the initial public offering. Stock Issuable For Settlement Of Deferred Underwriting Fees Stock issuable for settlement of deferred underwriting fees (in shares) Stock issuable for settlement of deferred underwriting fees Amount of liability of underwriting fees fair value. Liability of Underwriting Fees Fair Value Liability of underwriting fees Fair value of common shares issued for settlement of deferred underwriting fees. Fair Value Of Common Shares Issued For Settlement Of Deferred Underwriting Fees Fair value of common shares Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Represents information pertaining to pre funded warrants. Pre Funded Warrants [Member] Pre-funded warrants Pre-Funded Warrants Represents information pertaining to common stock purchase warrants Common Stock Purchase Warrants [Member] Common stock purchase warrants Represents information pertaining to placement agent warrants. Placement Agent Warrants [Member] Placement Agent Warrants Represents information relating to Best Efforts Public Offering. Best Efforts Public Offering [Member] Best efforts Subsidiary, Sale of Stock [Line Items] Description of Organization and Business Operations Number of warrants issued. Class of Warrant or Right, Number of Warrants Issued Pre-funded warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of warrants to purchase shares issued (in shares) Shares Issued, Price Per Share Offering price (in dollar per share) Per unit amount of warrants issued. Class of Warrant or Right, Issue Price Per Warrant Offering price of pre-funded warrants (in dollars per share) Sale of Stock, Consideration Received on Transaction Net proceeds Warrants and Rights Outstanding, Term Contractual term Period during which shares will not be issued after the closing date of the offering Period Of Non Issuance Of Common Stock Following Closing Date Period of non issuance of common stock following closing date Period during which common stock or any securities convertible into or exercisable or exchangeable for shares of common stock involving a variable rate transaction will not be issued after the closing date of the offering. Period Of Non Issuance Of Common Stock Involving Variable Rate Transaction Following Closing Date Period of non issuance of common stock involving variable rate transaction following closing date Percent of cash fee for placement agent, calculated on aggregate gross proceeds raised. Placement Agent Cash Fee, Percentage Placement agent fee, percent Amount of maximum out-of-pocket costs and expenses incurred in connection with the Offering that will be reimbursed Maximum Reimbursement For Placement Agent Expenses Placement agent fee, maximum reimbursement Number of shares of common stock sold in the offering, threshold percentage on the total number of outstanding shares. Percent Of Shares Issued In The Offering Percent of shares issued Percentage of the public offering price for the shares of common stock and common warrants offered in the Offering representing exercise price. Percent of Offering Price Representing Exercise Price Percent of offering price Related Party Transaction [Table] Chief Executive Officer [Member] Chief Executive Officer Represents information pertaining to public warrants. Public Warrants [Member] Public Warrants Represents information pertaining to private placement warrants. Private Placement Warrants [Member] Private placement warrants Related Party Transaction [Line Items] Significant Accounting Policies Related Party Transactions Amount of franchise tax expense and related interest and penalties incurred by the company during the period. Franchise Tax Expense Including Interest And Penalty Franchise tax, penalties and interest Cash Equivalents, at Carrying Value Cash equivalents Class of Warrant or Right, Outstanding Warrants issued (in shares) Warrants issued Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Incremental common shares (in shares) Incremental common shares Lessee, Operating Lease, Term of Contract Term of contract Number of Reportable Segments Number of reportable segment Number of Operating Segments Number of operating segment Unrecognized Tax Benefits Unrecognized tax benefits Uncertain tax positions Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Unrecognized tax benefits, interest and penalties accrued Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Represents the information pertaining to Metavagen License Agreement with respects to license right to develop, market and sell YN1203, InnoBation Bio CAR NK biomarkers, including devices, compounds and products used to detect analyte in body or tissue. CD47 License And Development Agreement With InnoBation [Member] CD47 License agreement with InnoBation Represents the information pertaining to Metavagen LLC ("Metavagen") owned by Chris Kim, the CEO of Liminatus. Curis Biotech Holdings Llc [Member] Curis Biotech Holdings LLC Represents information pertaining to InnoBation Bio Co. Ltd. Innobation Bio Co. Ltd [Member] Innobation Bio Co. Ltd Capital Units by Class [Axis] Capital Unit, Class [Domain] Capital Unit, Class A [Member] Class A Member Units Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] License Agreements Number of member units exchanged as a consideration for license rights to develop, market and sell YN1203, InnoBation Bio CAR NK biomarkers, including devices, compounds and products used to detect analyte in body or tissue. Number Of Units Exchange For License Rights Number of member units exchange for license rights to develop Number of member units exchange for license rights to develop, market and sell YN1203, InnoBation Bio CAR NK biomarker Value of membership interest exchange for license fees being offset to additional paid-in capital. License Rights, Value Of Units Offset From Additional Paid In Capital Value of membership interest offset to additional paid-in capital Amount of payment made for costs associated with clinical trials. Payment For Costs Associated With Clinical Trials Company issued a payment The estimated percentage of activities completed by the company as per agreement. Estimated Percentage Of Activities Completed Percentage of activities completed Amount of prepaid research and development classified as current. Prepaid Research And Development Expense, Current Prepaid research and development costs Represents information pertaining to Feelux Bonds. Feelux Bonds [Member] Feelux Bonds Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum [Member] Maximum Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input, Option Volatility [Member] Expected stock volatility Expected volatility Measurement Input, Risk Free Interest Rate [Member] Risk-free interest rate Measurement Input, Expected Dividend Rate [Member] Expected dividends Dividend yield Debt Instrument, Interest Rate, Stated Percentage Debt interest rate Interest rate Warrants and Rights Outstanding, Measurement Input Measurement input Debt Instrument, Unamortized Discount Debt discount Debt Instrument, Interest Rate, Effective Percentage Effective interest rate Number of shares of common stock issued in exchange for original debt being and member units being converted in connection with the consummation of business combination. Stock Issued During Period, Shares, Conversion Of Debt And Member Units Conversion of debt Interest Expense, Debt Interest expense relating to loan Represents information pertaining to Car-Tcellkor Loan. Car Tcellkor Loan [Member] Car-Tcellkor Loan Debt Instrument, Decrease, Forgiveness Consumption of outstanding principal Represents information pertaining to Valetudo Loan. Valetudo Loan [Member] Valetudo Loan Represents information pertaining to Valetudo December 2022 Loan. Valetudo December 2022 Loan [Member] Valetudo December 2022 Loan Represents information pertaining to Valetudo June 2023 Loans. Valetudo June 2023 Loans [Member] Valetudo June 2023 Loans Represents information pertaining to Valetudo June 2023 Loans. Valetudo June 2023 Loan One [Member] Valetudo June 2023 Loan One Represents information pertaining to Valetudo June 2023 Loan one. Valetudo June 2023 Loan Two [Member] Valetudo June 2023 Loan Two Represents information pertaining to Valetudo July 2023 Loan. Valetudo July 2023 Loan [Member] Valetudo July 2023 Loan Represents information pertaining to Valetudo August 2023 Loans. Valetudo August 2023 Loans [Member] Valetudo August 2023 Loans Represents information pertaining to Valetudo August 2023 Loans. Valetudo August 2023 Loan One [Member] Valetudo August 2023 Loan One Represents information pertaining to Valetudo August 2023 Loan one. Valetudo August 2023 Loan Two [Member] Valetudo August 2023 Loan Two Represents information pertaining toValetudo January 2024 Loans. Valetudo November 2023 Loan [Member] Valetudo November 2023 Loan Represents information pertaining to Valetudo January 2024 Loans. Valetudo January 2024 Loans [Member] Valetudo January 2024 Loans Represents information pertaining to Valetudo January 2024 Loan one. Valetudo January 2024 Loan One [Member] Valetudo January 2024 Loan One Represents information pertaining to Valetudo January 2024 Loan two. Valetudo January 2024 Loan Two [Member] Valetudo January 2024 Loan Two Represents information pertaining to Valetudo Therapeutics LLC. Valetudo Therapeutics LLC [Member] Valetudo Therapeutics LLC Amount of repayment of membership interest. Repayment Of Membership Interest Repayment of membership interest Debt Conversion, Converted Instrument, Amount Conversion of outstanding principal Represents information pertaining to Ewon Loan. Ewon Loan [Member] Ewon Loan Represents information pertaining to Ewon December 2022 Loan. Ewon December 2022 Loan [Member] Ewon December 2022 Loan Represents information pertaining to Ewon September 2023 Loan. Ewon September 2023 Loan [Member] Ewon September 2023 Loan Represents information pertaining to Ewon December 2023 Loan. Ewon December 2023 Loan [Member] Ewon December 2023 Loan Represents information pertaining to Ewon Comfortech Co, Ltd. Ewon Comfortech Co Ltd [Member] Ewon Comfortech Co Ltd Represents information pertaining to Prophase Loan. Prophase Loan [Member] Prophase Loan Represents information pertaining to Prophase February 2024 Loan. Prophase February 2024 Loan [Member] Prophase February 2024 Loan Represents information pertaining to Prophase March 2024 Loan. Prophase March 2024 Loan [Member] Prophase March 2024 Loan Represents information pertaining to Prophase April 2024 Loan. Prophase April 2024 Loan [Member] Prophase April 2024 Loan Represents information pertaining to Prophase May 2024 Loans. Prophase May 2024 Loans [Member] Prophase May 2024 Loans Represents information pertaining to Prophase July 2024 Loans. Prophase July 2024 Loans [Member] Prophase July 2024 Loans Represents information pertaining to Prophase August 2024 Loans. Prophase August 2024 Loans [Member] Prophase August 2024 Loans Represents information pertaining to Prophase February 2025 Loans. Prophase February 2025 Loans [Member] Prophase February 2025 Loan Represents information pertaining to Prophase March 2025 Loans. Prophase March 2025 Loans [Member] Prophase March 2025 Loans Represents information pertaining to Prophase April 2025 Loans. Prophase April 2025 Loans [Member] Prophase April 2025 Loans Represents information pertaining to Prophase Sciences LLC . Prophase Sciences LLC [Member] Prophase Represents information pertaining to Hana Loans. Hana Loans [Member] Hana Loans Represents information pertaining to Hana August 2024 Loans. Hana August 2024 Loans [Member] Hana August 2024 Loans Represents information pertaining to Hana Immunotherapeutics, LLC. Hana Immunotherapeutics, LLC [Member] Hana Immunotherapeutics, LLC Represents information pertaining to Amantes Loans. Amantes Loans [Member] Amantes Loans Represents information pertaining to Amantes November 2024 Loans. Amantes November 2024 Loans [Member] Amantes November 2024 Loans Represents information pertaining to Amantes January 2025 Loans. Amantes January 2025 Loans [Member] Amantes January 2025 Loans Amantes January 2025 Loans Represents information pertaining to Amantes LLC . Amantes LLC [Member] Amantes Financial Instrument [Axis] Financial Instruments [Domain] Represents information pertaining to employment agreement. Employment Agreement [Member] Employment Agreement Short-Term Debt [Table] Represents information pertaining to Prophase February 2025 Loan. Prophase February 2025 Loan [Member] Prophase February 2025 Loan Prophase February 2025 Loan Represents information pertaining to Prophase March 2025 Loan. Prophase March 2025 Loan [Member] Prophase March 2025 Loan Prophase March 2025 Loan Represents information pertaining to Valetudo December 2022 Loans. Valetudo December 2022 Loans [Member] Valetudo Loan Short-Term Debt [Line Items] Debt Class of Warrant or Right [Table] Represents information pertaining to common stock and pre-funded warrants. Common Stock and Pre Funded Warrants [Member] Common stock and Pre-Funded Warrants Represents information pertaining to Alta Partners Llc.. Alta Partners Llc [Member] Alta Partners Llc Represents information pertaining to Clear Street LLC Clear Street Llc [Member] Clear Street Llc Class of Warrant or Right [Line Items] Stockholders' Equity Stockholders' Equity Number of shares issued for surrender and cancellation of warrants. Shares Issued For Surrender And Cancellation Of Warrants Number of shares issued for surrender and cancellation of warrants Issuance of common stock in connection with the surrender of warrants (in shares) Number of warrants surrendered and canceled. Class Of Warrant Or Right, Number Of Securities Surrendered And Canceled Surrender and cancellation of warrants to purchase shares of common stock The fair value of common stock issued. Fair Value of Common Stock Issued Fair value of common stock The fair value of warrants surrendered. Fair Value of Warrants Surrendered Fair value of warrants surrendered The profit or loss on exchange of common stock for surrender of warrants classified as non-operating income. Represents the difference in the fair value of common stock and warrants. Gain (Loss) on Issuance of Common Stock for Warrants Loss on issuance of common stock in connection with the surrendar of warrants Loss on issuance of common stock Loss on exchange of common stock for warrants Number of warrants issued on conversion. Class of Warrant or Right, Number of Warrants Issued on Conversions Pre-funded warrants issued on conversion (in shares) Share Price Closing stock price The number of warrants exercised. Class of Warrant or Right, Number Of Warrants Exercised Pre-Funded warrants exercised Number of votes for each share of common stock. Common Stock, Number Of Votes Per Share Number of votes per share The threshold period during which a written notice is required for redemption of warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Class Of Warrant Or Right, Threshold Written Notice Period For Redemption Of Warrants Threshold written notice period for redemption of warrants The threshold trigger price for redemption of warrants. Class Of Warrant Or Right, Threshold Share Price Trigger For Redemption Threshold Share Price for redemption of warrants Threshold number of specified trading days for stock price trigger considered for redemption of warrants. Class Of Warrant Or Right, Redemption Of Warrants Or Rights, Threshold Trading Days Threshold number of specified trading days for stock price Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants. Class Of Warrant Or Right, Redemption Of Warrants Or Rights, Threshold Consecutive Trading Days Threshold number of specified consecutive trading days for stock price Fair Value Measurement Inputs and Valuation Techniques [Table] Measurement Input, Expected Term [Member] Expected life of warrants (years) Represents information pertaining to common stock warrants and placement agent warrants. Common Stock Warrants and Placement Agent Warrants [Member] Common Stock Warrants and Placement Agent Warrants Fair Value Measurement Inputs and Valuation Techniques [Line Items] Stockholder's Equity Represents information pertaining to common stock warrants. Common Stock Warrants [Member] Common Stock Warrants The gross cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). Gross Proceeds from Issuance of Warrants Allocated Gross Proceeds The net cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). Net Proceeds from Issuance of Warrants Allocated Net Proceeds Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table] Represents the information pertaining to Fee reduction agreement. Fee Reduction Agreement [Member] Fee Reduction Agreement Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] Commitments and Contingencies Short-Term Lease, Cost Short term lease expense Loss Contingency, Damages Awarded, Value Loss contingency on damaged value Litigation Settlement Interest Litigation settlement interest Represents the percentage of underwriting discount on gross proceeds of the IPO. Underwriting Discount as Percentage of Gross Proceeds from Initial Public Offering Underwriting discount (in percentage) Amount of the carrying value as of balance sheet date of underwriting fees payable or classified as noncurrent. Underwriting Costs Noncurrent Underwriting discount Represents the percentage of deferred underwriting discount on gross proceeds of the IPO. Deferred Underwriting Discount as Percentage of Gross Proceeds from Initial Public Offering Deferred underwriting discount (in percentage) Amount of the carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent. Deferred Offering Costs Noncurrent Deferred underwriting discount The amount paid in cash for offering costs. Payment of Offering Costs in Cash Underwriting discount paid in cash The amount paid in shares for offering costs. Underwriting discount paid in securities Underwriting discount paid in securities The maximum number of shares issuable to underwriters. Maximum Numbers Of Shares Issuable Number of shares issuable to underwriters Amount of deferred underwriting fee payable settled upon consummation of business combination. Deferred Underwriting Fee Payable Settled Upon Consummation Of Business Combination Deferred underwriting fees settled Amount of deferred underwriting fee payable settled in shares upon consummation of business combination. Deferred Underwriting Fee Payable Settled In Shares Upon Consummation Of Business Combination Deferred underwriting fee payable settled in shares Amount of deferred underwriting fee payable settled in cash upon consummation of business combination. Deferred Underwriting Fee Payable Settled In Cash Upon Consummation Of Business Combination Deferred underwriting fee payable settled in cash Amount of deferred underwriting fee waived upon consummation of business combination. Deferred Underwriting Fee Waived Upon Consummation Of Business Combination Deferred underwriting fee waived Remaining amount of deferred underwriting fee settled upon consummation of combined company next share offering. Deferred Underwriting Fee, Remaining Amount Settlement Upon Consummation Of Combined Company Next Share Offering Remaining amount of deferred underwriting fee settled Represents the threshold period for settling remaining deferred underwriting fee from the date of business combination. Threshold Period For Remaining Deferred Underwriting Fee Settlement From Date of Business Combination Threshold period for settling remaining deferred underwriting fee Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Fair Value Measurements Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements Financial Liabilities Fair Value Disclosure Warrant liability Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 3 [Member] Fair value inputs level 3 Warrant [Member] Warrants Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Ending balance, fair value Beginning balance, fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Initial measurement at the Closing Date Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Change in fair value Amount of accrued maintenance fee as of balance sheet date. Accrued Maintenance Fee, Current Accrued maintenance fee Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. Common Stock, Share Outstanding Common stock, shares outstanding Income Taxes Income Tax Disclosure [Text Block] Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of components of income tax provision (benefit) Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of reconciliation of the effective income tax rate Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of components of deferred tax assets and liabilities Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event Financing Receivable, Allowance for Credit Loss, Current Credit losses relating to loan receivable Represents the information pertaining to license and development agreement with TDT (the "CAR-T License"), whereby the Company received an exclusive license to develop and commercialize chimeric antigen receptor ("CAR-T") products and a non-exclusive license to develop and commercialize companion diagnostics used to monitor treatment with a CAR-T product (the "CAR-T Diagnostics"). License And Development Agreement With Tdt [Member] License And Development Agreement With TDT Product and Service [Axis] Product and Service [Domain] Represents the information pertaining to product being commercialize chimeric antigen receptor ("CAR-T") and CAR-T Diagnostics. Commercialize Chimeric Antigen Receptor And CAR-T Diagnostics [Member] CAR-T products and CAR-T Diagnostics Represents the information pertaining to Phase II and Phase III clinical trials of CAR-T product. Phase II and Phase III Clinical Trials Of Car T Product [Member] Phase II and Phase III clinical trials of CAR-T Product Scenario [Axis] Scenario [Domain] Represents the information pertaining scenario being the scenario prior to the completion of the Phase I and Phase II clinical trials for the CAR-T product. Scenario, Prior To Completion of Phase One and Two Clinical Trials for CAR-T Product [Member] Prior to the completion of the Phase I and Phase II clinical trials for the CAR-T product Represents the information pertaining scenario being the net sale of period from the first commercial sale of the CAR-T product or CAR-T Diagnostic until the product's patent expires in an individual country. Annual Sales Of Period From First Commercial Sale Until Patent Expires [Member] Net sales of period from first commercial sale until patent expires Represents the information pertaining scenario being the net sale of period of 10 years from the first commercial sale of the CAR-T product or CAR-T Diagnostic until the product's patent expires in an individual country. Ten Years Period From First Commercial Sale Of Product [Member] 10 years from first commercial sale of products Minimum [Member] Minimum Amount of upfront payment of license agreement fee. Upfront Payment Of License Agreement Fees Upfront payment of license agreement fees Cost, Maintenance Annual maintenance fees Percentage of interest rate of short-term debt being converted from the unpaid annual maintenance fees. Unpaid Annual Maintenance Fees, Short - Term Debt, Interest Rate Unpaid annual maintenance fees, short term debt interest rate (%) Amount of license milestone commitment fund obligated to pay for each phase. License Milestone Commitment Fund Payable For Each Phase Amount of fund obligated to advance for each phase Number of milestone developmental and regulatory milestone payments for first product development. Number Of Milestone Payments For First Product Development Number of developmental and regulatory milestone payments for first product development Amount of maximum aggregate milestone commitment fund for first product development. License Maximum Aggregate Milestone Commitments Fund For First Product Development Maximum aggregate milestone commitment fund for first product development Number of milestone developmental and regulatory milestone payments for each additional product development. Number Of Milestone Payments For Each Additional Product Development Number of developmental and regulatory milestone payments for each additional product development Amount of maximum milestone commitment fund for each additional product development. License Maximum Milestone Commitment Fund For Each Additional Product Development Maximum milestone commitment fund for each additional product development Percentage of royalty fees Royalty Fees, Percentage Percentage of royalty fees (%) Number of years from the first commercial sale of CAR-T product or CAR-T Diagnostic. Royalty Fees, Number of Years From First Commercial Sale Of Products Number of years from first commercial sale of products (in years) Represents the information pertaining to license and development agreement with TDT (the "Vaccine License"), whereby the Company received an exclusive license to develop and commercialize vaccine products (the "Vaccine Products") and a non-exclusive license to develop and commercialize companion diagnostics used to monitor treatment with a Vaccine Product (the "Vaccine Diagnostics"). Vaccine License And Development Agreement With Tdt [Member] Vaccine license and development agreement with TDT Represents the information pertaining to CAR-T Products and Vaccine Licenses. CAR T License And Vaccine License With Tdt [Member] CAR-T License and Vaccine License with TDT Represents the information pertaining to product being vaccine products (the "Vaccine Products") and Vaccine Diagnostics. Vaccine Products And Vaccine Diagnostics [Member] Vaccine Products and Vaccine Diagnostics Amount of license agreement incurred in maintenance fees. License agreement maintenance fees Maintenance fee Amount owes pursuant to termination of license agreements by TDT. License Agreements Termination, Amount Due Amount owes pursuant to termination of license agreement Represents information pertaining to Viral Gene. Viral Gene [Member] Viral Gene Other Receivables, Net, Current Due from related party, current Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Change in valuation allowance The amount of research and development expense subject to mandatory capitalization. Research and Development Expense, Mandatory Capitalization Research and development Operating Loss Carryforwards Net operating losses Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. Federal Income Tax Expense Subject To Limitation In Use Federal income tax liabilities, subject limitations Percentage of state statutory tax rate applicable to pretax income (loss). Statutory State Income Tax Rate California income tax rate Income Tax Examination, Penalties and Interest Accrued Accrued interest or penalties Income Taxes Paid, Net Income tax obligations Federal Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract] State and Local Deferred State and Local Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) Income tax provision expense/(benefit) Income tax provision Effective Income Tax Rate Reconciliation, Percent [Abstract] Effective Income Tax Rate Reconciliation, Percent Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Statutory federal income tax rate Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent State taxes, net of federal expense Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to gain loss on exchange of common stock for warrants Effective Income Tax Rate Reconciliation, Gain (Loss) On Exchange Of Common Stock, Percent Loss on exchange of common stock for warrants Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value of common stock to be issued for contingent liability Effective Income Tax Rate Reconciliation, Fair Value Of Common Stock For Contingent Liability, Percent Fair value of common stock to be issued for contingent liability Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Other permanent differences Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Valuation allowance Effective Income Tax Rate Reconciliation, Percent Income tax provision expense/(benefit) Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Statutory federal income tax rate Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount State taxes, net of federal expense Effective Income Tax Rate Reconciliation, State and Local Jurisdiction, Contribution Greater than 50 Percent, Tax Effect [Extensible Enumeration] Effective Income Tax Rate Reconciliation, State and Local Jurisdiction, Contribution Greater than 50 Percent, Tax Effect [Extensible Enumeration] Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to gain (loss) on exchange of common stock for warrants Effective Income Tax Rate Reconciliation, Gain (Loss) On Exchange Of Common Stock, Amount Loss on exchange of common stock for warrants Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value of common stock to be issued for contingent liability Effective Income Tax Rate Reconciliation, Fair Value Of Common Stock For Contingent Liability, Amount Fair value of common stock to be issued for contingent liability Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Other permanent differences Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Valuation allowance Components of Deferred Tax Assets [Abstract] Deferred tax asset Deferred Tax Assets, Operating Loss Carryforwards Net operating loss carryforward Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from startup expenses Deferred Tax Assets, Startup Expenses Startup expenses Deferred Tax Asset, Interest Carryforward Section 163(j) - Interest Deferred Tax Assets, Gross Total deferred tax assets Deferred Tax Assets, Valuation Allowance Less: valuation allowance Deferred Tax Assets, Net of Valuation Allowance Deferred tax asset, net of valuation allowance Subsequent Event [Table] Subsequent Event [Line Items] Subsequent Events